^
Association details:
| Biomarker: | NF2 E108X |
|---|---|
| Cancer: | Neurofibrosarcoma |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.
Published date:
05/19/2021
Excerpt:
Table summarizes matched therapies in responders....Malignant peripheral nerve sheath tumor...NF2: E108*...Temsirolimus + cyclophosphamide + vinorelbine – PR, 13 mo. Everolimus - PD.
DOI:
10.1200/JCO.2021.39.15_suppl.11538
